Compare · ILMNV vs RVTY
ILMNV vs RVTY
Side-by-side comparison of Illumina Inc. (ILMNV) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMNV and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY carries a market cap of $17.26B.
- RVTY has hit the wire 5 times in the past 4 weeks while ILMNV has been quiet.
- RVTY has more recent analyst coverage (23 ratings vs 0 for ILMNV).
- Company
- Illumina Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- -
- $17.26B
- 1M return
- -
- +4.01%
- 1Y return
- -
- +60.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 23
Latest ILMNV
- SVP, Chief Commercial Officer Cunningham Everett was granted 36,860 shares (SEC Form 4)
- Director Ullem Scott B. was granted 205 shares, increasing direct ownership by 5% to 4,550 units (SEC Form 4)
- Amendment: Illumina Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: Illumina Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Latest RVTY
- Revvity to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Revvity
- Revvity to Host Investor Day
- VP and CAO Gonzales Anita sold $13,060 worth of shares (84 units at $155.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Revvity to Hold Earnings Call on November 3, 2026
- Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
- Officer Krakowiak Maxwell sold $235,728 worth of shares (1,631 units at $144.53) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 14,781 units (SEC Form 4)
- Officer Vohra Tajinder S sold $1,032,650 worth of shares (7,330 units at $140.88) as part of a pre-agreed trading plan, decreasing direct ownership by 52% to 6,635 units (SEC Form 4)
- UBS resumed coverage on Revvity with a new price target
- Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery